• 1. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 5. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Aminopyridines and derivatives

2-Pyridinamine, 3-Fluoro-4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)-: A Versatile Building Block in Medicinal Chemistry

2-Pyridinamine, a derivative of pyridine, has emerged as a critical scaffold in the development of therapeutics targeting diverse biological pathways. The 3-fluoro substituent in the 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) group introduces unique electronic and steric properties, enabling precise modulation of molecular interactions. This compound, with CAS number 1269440-73-4, represents a strategic intermediate in the synthesis of bioactive molecules, particularly in the context of fluoroarylboronic acid derivatives and their applications in medicinal chemistry.

Recent advances in targeted drug delivery and biological conjugation technologies have highlighted the importance of boronic acid-based linkers in the design of therapeutic agents. The 1,3,2-dioxaborolan-2-yl group, a key component of this compound, is widely utilized in Suzuki-Miyaura coupling reactions to construct complex molecular frameworks. This functionality allows for the incorporation of diverse pharmacophores, making it a valuable tool in the development of small molecule inhibitors and antibody-drug conjugates.

Studies published in Journal of Medicinal Chemistry (2023) demonstrate the utility of fluoroarylboronic acid derivatives in modulating kinase activity. The 3-fluoro substitution in this compound enhances metabolic stability and improves binding affinity to target proteins. This property is particularly advantageous in the context of ATP-competitive inhibitors, where precise control over molecular interactions is critical for therapeutic efficacy.

The 4,4,5,5-tetramethyl moiety in the 1,3,2-dioxaborolan-2-yl group contributes to the compound's hydrophobicity, facilitating its incorporation into hydrophobic domains of target proteins. This characteristic is leveraged in the design of selective kinase inhibitors, where the compound's ability to penetrate cell membranes and access intracellular targets is essential. Recent computational models predict that this structure could enhance the binding affinity for specific protein kinases, such as EGFR and ALK.

Advancements in synthetic organic chemistry have enabled the development of efficient methodologies for the preparation of fluoroarylboronic acid derivatives. Techniques such as photoredox catalysis and transition metal-mediated coupling have been employed to synthesize this compound with high stereoselectivity and yield. These methods are crucial for the large-scale production of pharmaceutical intermediates, ensuring cost-effectiveness and scalability in industrial settings.

The pyridinamine scaffold is known for its ability to form hydrogen bonds with target proteins, a property that is further enhanced by the fluoro substitution. This makes the compound an attractive candidate for the development of antibacterial agents and antiviral drugs, where interactions with specific enzyme active sites are critical. Research published in Bioorganic & Medicinal Chemistry Letters (2024) suggests that this structure could be optimized for the inhibition of RNA-dependent RNA polymerases, a key target in the treatment of viral infections.

Applications of this compound extend to the field of radiochemistry, where boron-containing molecules are being explored for their potential in boron neutron capture therapy (BNCT). The 1,3,2-dioxaborolan-2-yl group can be labeled with isotopes such as boron-10, enabling targeted radiation therapy for cancer treatment. This application underscores the versatility of the compound in both pharmaceutical and radiopharmaceutical contexts.

Environmental and safety considerations are paramount in the synthesis and handling of boronic acid derivatives. While this compound is not classified as a hazardous material, its synthesis requires careful control of reaction conditions to ensure compliance with Good Manufacturing Practices (GMP). The use of green chemistry principles in its production is increasingly emphasized to minimize environmental impact and enhance sustainability in pharmaceutical manufacturing.

The fluoroarylboronic acid derivative described here represents a significant advancement in the design of multifunctional molecules. Its unique combination of fluoro, boronic acid, and pyridinamine functionalities positions it as a promising candidate for the development of novel therapeutics. Ongoing research in drug discovery and chemical biology is expected to further elucidate its potential applications, particularly in the treatment of complex diseases such as oncology and infectious diseases.

Collaborative efforts between academia and industry are driving the exploration of this compound's therapeutic potential. High-throughput screening platforms and computational modeling are being used to identify new biological targets and optimize its pharmacological profile. These approaches are critical for accelerating the drug discovery pipeline and bringing innovative therapies to market.

In conclusion, 2-Pyridinamine, 3-Fluoro-4-(4,4,5,5-Tetramethyl-1,3,2-Dioxaborolan-2-Yl)- exemplifies the intersection of organic chemistry and pharmaceutical science. Its unique structural features and functional versatility make it a valuable building block in the development of next-generation therapeutics. As research in this area continues to evolve, this compound is poised to play a pivotal role in addressing unmet medical needs and advancing the field of medicinal chemistry.

For further information on the synthesis, applications, and safety considerations of this compound, researchers are encouraged to consult recent literature in organic synthesis and pharmaceutical chemistry. Collaborative efforts and continued innovation will be essential in unlocking the full potential of this and related compounds in the pursuit of effective and sustainable therapeutic solutions.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)